Abstract
Vaccination can be considered one of the most beneficial intervention to control infectious diseases in the history of mankind. In recent years, an intense interest has raised upon the development of novel vaccination approaches, especially against enteric pathogens. The interest has been fueled by knowledge of the molecular bases of pathogenesis of infectious diseases and by information regarding the biology of pathogens and their intimate relationship with the host. The use of attenuated bacteria in vaccine formulations has significant advantages compared to that of inactivated whole microbes, because by inducing a mild and limited infection they stimulate a robust and protective immune response. In addition, being able to naturally colonize the host, they can be used for mucosal delivery. Over the past few years, the possibility to induce oral immunization has been considered an attractive strategy which opened a new area of exploration. The development of vaccine against enteric pathogens is a challenging opportunity because a large number of bacterial pathogens exploit mucosal surface to penetrate and survive into the host. This chapter is aiming to make an overview of the progresses in the understanding of the interaction between host and enteric pathogens and in the development of the mucosal vaccines for human bacterial enteric diseases with an important impact on public health.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Ammendola S, Pasquali P, Pistoia C, Petrucci P, Petrarca P, Rotilio G, Battistoni A (2007) The high affinity Zn2+ uptake system ZnuABC is required for bacterial zinc homeostasis in intracellular environments and contributes to virulence of Salmonella enteric. Infect Immun 75:5867–5876
Anh DD, Canh DG, Lopez AL, Thiem VD, Long PT, Son NH, Deen J, von Seidlein L, Carbis R, Han SH, Shin SH, Attridge S, Holmgren J, Clemens J (2007) Safety and immunogenicity of a reformulated Vietnamese bivalent killed, whole-cell, oral cholera vaccine in adults. Vaccine 25:1149–1155
Arumugam M, Raes J, Pelletier E, LePaslier D, Yamada T, Mende DR, Fernandes GR, Tap J, Bruls T, Batto JM, Bertalan M, Borruel N, Casellas F, Fernandez L, Gautier L, Hansen T, Hattori M, Hayashi T, Kleerebezem M, Kurokawa K, Leclerc M, Levenez F, Manichanh C, Nielsen HB, Nielsen T, Pons N, Poulain J, Qin J, Sicheritz-Ponten T, Tims S, Torrents D, Ugarte E, Zoe-tendal EG, Wang J, Guarner F, Pedersen O, DeVos WM, Brunak S, Dore J, Consorti M, Weissenbach J, Ehrlich SD, Bork P, Antolin M, Artiguenave F, Blottiere HM, Almeida M, Brechot C, Cara C, Chervaux C, Cultrone A, Delorme C, Denariaz G, Dervyn R, Foerstner KU, Friss C, Van DeGuchte M, Guedon E, Haimet F, Huber W, Van Hylckama-Vlieg J, Jamet A, Juste C, Kaci G, Knol J, Lakhdari O, Layec S, LeRoux K, Maguin E, Merieux A, MeloMinardi R, M’Rini C, Muller J, Oozeer R, Parkhill J, Renault P, Rescigno M, Sanchez N, Sunagawa S, Torrejon A, Turner K, Vandemeulebrouck G, Varela E, Winogradsky Y, Zeller G (2011) Enterotypes of the human gut microbiome. Nature 43:174–180
Belkaid Y, Rouse BT (2005) Natural regulatory T cells in infectious disease. Nat Immunol 6:353–360
Bishop AL, Camilli A (2011) Vibrio cholerae: lessons for mucosal vaccine design. Expert Rev Vaccines 10:79–94
Blaschitz C, Raffatellu M (2010) Th17 cytokines and the gut mucosal barrier. J Clin Immunol 30:196–203
Brandtzaeg P (2007) Induction of secretory immunity and memory at mucosal surfaces. Vaccine 25:5467–5484
Brandtzaeg P (2010) Food allergy: separating the science from the mythology. Nat Rev Gastroenterol Hepatol 7:380–400
Calain P, Chaine JP, Johnson E, Hawley ML, O’Leary MJ, Oshitani H, Chaignat CL (2004) Can oral cholera vaccination play a role in controlling a cholera outbreak? Vaccine 22:2444–2451
Caprioli A, Morabito S, Brugère H, Oswald E (2005) Enterohaemorrhagic Escherichia coli: emerging issues on virulence and modes of transmission. Vet Res 36:289–311
Cash RA, Music SI, Libonati JP, Craig JP, Pierce NF, Hornick RB (1974) Response of man to infection with Vibrio cholerae. II. Protection from illness afforded by previous disease and vaccine. J Infect Dis 130:325–333
Cerutti A (2008) The regulation of IgA class switching. Nat Rev Immunol 8:421–434
Chen Y, Chou K, Fuchs E, Havran WL, Boismenu R (2002) Protection of the intestinal mucosa by intraepithelial γ δ T cells. Proc Natl Acad Sci USA 99:14338–14343
Clemens JD, Sack DA, Harris JR, Van Loon F, Chakraborty J, Ahmed F, Rao MR, Khan MR, Yunus M, Huda N, Stanton BF, Kay BA, Eeckels R, Clemens JD, Rao MR, Kay BA, Sack DA, Harris JR, Stanton BF, Walter S, Eeckels R, Svennerholm A-M, Holmgren J (1990) Field trial of oral cholera vaccines in Bangladesh: results from three-year follow-up. Lancet 335:270–273
Clemens JD, Sack DA, Ivanoff B (2001) Misleading negative findings in a field trial of killed, oral cholera vaccine in Peru. J Infect Dis 183:1306–1309
Cohen MB, Giannella RA, Bean J, Taylor DN, Parker S, Hoeper A, Wowk S, Hawkins J, Kochi SK, Schiff G, Killeen KP (2002) Randomized, controlled human challenge study of the safety, immunogenicity, and protective efficacy of a single dose of Peru-15, a live attenuated oral cholera vaccine. Infect Immun 70:1965–1970
Daley A, Randall R, Darsley M, Choudhry N, Thomas N, Sanderson IR, Croft NM, Kelly P (2007) Genetically modified enterotoxigenic Escherichia colivaccines induce mucosal immune responses without inflammation. Gut 56:1550–1556
De Calisto J, Villablanca EJ, Wang S, Bono MR, Rosemblatt M, Mora JR (2012) T-cell homing to the gut mucosa: general concepts and methodological considerations. Methods Mol Biol 757:411–434
Dougan G, John V, Palmer S, Mastroeni P (2011) Immunity to salmonellosis. Immunol Rev 240:196–210
Eberl G (2010) A new vision of immunity: homeostasis of the superorganism. Mucosal Immunol 3:450–460
Faria AM, Weiner HL (2005) Oral tolerance. Immunol Rev 206:232–259
Finkelstein RA (1962) Vibriocidal antibody inhibition (VAI) analysis: a technique for the identification of the predominant vibriocidal antibodies in serum and for the detection and identification of Vibrio cholerae antigens. J Immunol 89:264–271
Fraser A, Paul M, Goldberg E, Acosta CJ, Leibovici L (2007) Typhoid fever vaccines: systematic review and meta-analysis of randomised controlled trials. Vaccine 25:7848–7857
Gaastra W, Svennerholm AM (1996) Colonization factors of human enterotoxigenic Escherichia coli (ETEC). Trends Microbiol 4:444–452
Gaboriau-Routhiau V, Rakotobe S, Lecuyer E, Mulder I, Lan A, Bridonneau C, Rochet V, Pisi A, De Paepe M, Brandi G, Eberl G, Snel J, Kelly D, Cerf-Bensussan N (2009) The keyrole of segmented filamentous bacteria in the coordinated maturation of gut helper T cell responses. Immunity 31:677–689
García L, Jidy MD, García H, Rodríguez BL, Fernández R, Año G, Cedré B, Valmaseda T, Suzarte E, Ramírez M, Pino Y, Campos J, Menéndez J, Valera R, González D, González I, Pérez O, Serrano T, Lastre M, Miralles F, Del Campo J, Maestre JL, Pérez JL, Talavera A, Pérez A, Marrero K, Ledón T, Fando R (2005) The vaccine candidate Vibrio cholerae 638 is protective against cholera in healthy volunteers. Infect Immun 73:3018–3024
Girard MP, Steele D, Chaignat CL, Kieny MP (2006) A review of vaccine research and development: human enteric infections. Vaccine 24:2732–2750
Great Britain Medical Research Council (1956) BCG and whole bacillus vaccines in the prevention of tuberculosis in adolescence and early life. Br Med J 1:413–466
Holmgren J, Czerkinsky C (2005) Mucosal immunity and vaccines. Nat Med 11:S45–S53
Ismail AS, Behrendt CL, Hooper LV (2009) Reciprocal interactions between commensal bacteria and γδ intraepithelial lymphocytes during mucosal injury. J Immunol 182:3047–3054
Ismail AS, Severson KM, Vaishnava S, Behrendt CL, Yu X, Benjamin JL, Ruhn KA, Hou B, DeFranco AL, Yarovinsky F, Hooper Lora V (2011) γδ intraepithelial lymphocytes are essential mediators of host-microbial homeostasis at the intestinal mucosal surface. Proc Natl Acad Sci USA 108:8743–8748
Ivanov II, Atarashi K, Manel N, Brodie EL, Shima T, Karaoz U, Wei D, Goldfarb KC, Santee CA, Lynch SV, Tanoue T, Imaoka A, Itoh K, Takeda K, Umesaki Y, Honda K, Littman DR (2009) Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell 139:485–498
Kosiewicz MM, Zirnheld A, Alard P (2011) Gut microbiota, immunity, and disease: a complex relationship. Front Microbiol 2:1–11
Kotloff KL, Nataro JP, Losonsky GA, Wasserman SS, Hale TL, Taylor DN, Sadoff JC, Levine MM (1995) A modified Shigella volunteer challenge model in which the inoculum is administered with bicarbonate buffer: clinical experience and implications for Shigella infectivity. Vaccine 13:1488–1494
Lavelle EC, O’Hagan DT (2006) Delivery systems and adjuvants for oral vaccines. Expert Opin Drug Deliv 3:747–762
Lee SH, Hava DL, Waldor MK, Camilli A (1999) Regulation and temporal expression patterns of Vibrio cholerae virulence genes during infection. Cell 99:625–634
Lehner MD, Hartung T (2002) Endotoxin tolerance mechanisms and beneficial effects in bacterial infection. Rev Physiol Biochem Pharmacol 144:95–141
Levine MM, Kotloff KL, Barry EM, Pasetti MF, Sztein MB (2007) Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road. Nat Rev Microbiol 5:540–553
Liang W, Wang S, Yu F, Zhang L, Qi G, Liu Y, Gao S, Kan B (2003) Construction and evaluation of a safe, live, oral Vibrio cholerae vaccine candidate, IEM108. Infect Immun 71:5498–5504
Lindow JC, Fimlaid KA, Bunn JY, Kirkpatrick BD (2011) Antibodies in action: role of human opsonins in killing Salmonella enterica Serovar Typhi. Infect Immun 79:3188–3194
Lonnroth I, Holmgren J (1973) Subunit structure of cholera toxin. J Gen Microbiol 76:417–427
Lucas MES, Deen JL, von Seidlein L, Wang XY, Ampuero J, Puri M, Ali M, Ansaruzzaman M, Amos J, Macuamule A, Cavailler P, Guerin PJ, Mahoudeau C, Kahozi-Sangwa P, Chaignat CL, Barreto A, Songane FF, Clemens JD (2005) Effectiveness of mass oral cholera vaccination in Beira, Mozambique. N Engl J Med 352:757–767
Mahalanabis D, Lopez AL, Sur D, Manna B, Kanungo S, von Seidlein L, Carbis R, Han SH, Shin SH, Attridge S, Rao R, Holmgren J, Clemens J, Bhattacharya SK (2008) A randomized, placebo controlled trial of the bivalent killed, whole-cell, oral cholera vaccine in adults and children in a cholera endemic area in Kolkata, India. PLoS One 3:e2323
Mahalanabis D, Ramamurthy T, Nair GB, Ghosh A, Shaikh S, Sen B, Thungapathra M, Ghosh RK, Pazhani GP, Nandy RK, Jana S, Bhattacharya SK (2009) Randomized placebo controlled human volunteer trial of a live oral cholera vaccine VA1.3 for safety and immune response. Vaccine 27:4850–4856
Mantis NJ, Rol N, Corthésy B (2011) Secretory IgA’s complex roles in immunity and mucosal homeostasis in the gut. Mucosal Immunol 4:603–611
Masopust D, Vezys V, Wherry EJ, Barber DL, Ahmed R (2006) Cutting edge: gut microenvironment promotes differentiation of a unique memory CD8 T cell population. J Immunol 76:2079–2083
Mastroeni P, Villarreal-Ramos B, Hormaeche CE (1993) Adoptive transfer of immunity to oral challenge with virulent salmonellae in innately susceptible BALB/c mice requires both immune serum and T cells. Infect Immun 61:3981–3984
Mazmanian SK, Round JL, Kasper DL (2008) A microbial symbiosis factor prevents intestinal inflammatory disease. Nature 453:620–625
Mbow ML, De Gregorio E, Valiante NM, Rappuoli R (2011) New adjuvants for human vaccines. Curr Opin Immunol 22:411–416
McGuckin MA, Linden SK, Sutton P, Florin TH (2011) Mucin dynamics and enteric pathogens. Nat Rev Microbiol 9:265–278
McKenzie R, Bourgeois AL, Engstrom F, Hall E, Chang HS, Gomes JG, Kyle JL, Cassels F, Turner AK, Randall R, Darsley M, Lee C, Bedford P, Shimko J, Sack DA (2006) Comparative safety and immunogenicity of two attenuated enterotoxigenic Escherichia coli vaccine strains in healthy adults. Infect Immun 74:994–1000
McKenzie R, Darsley M, Thomas N, Randall R, Carpenter C, Forbes E, Finucane M, Sack RB, Hall E, Bourgeois AL (2008) A double-blind, placebo-controlled trial to evaluate the efficacy of PTL-003, an attenuated enterotoxigenic E. coli (ETEC) vaccine strain, in protecting against challenge with virulent ETEC. Vaccine 26:4731–4739
Meeusen EN (2011) Exploiting mucosal surfaces for the development of mucosal vaccines. Vaccine 29:8506–8511
Mestecky J (1987) The common mucosal immune system and current strategies for induction of immune responses in external secretions. J Clin Immunol 7:265–276
Mittrucker HW, Kaufmann SHE (2004) Mini-review: regulatory T cells and infection: suppression revisited. Eur J Immunol 34:306–312
Mosley WH, Ahmad S, Benenson AS, Ahmed A (1968) The relationship of vibriocidal antibody titre to susceptibility to cholera in family contacts of cholera patients. Bull World Health Organ 38:777–785
Muller C, Bang IS, Velayudhan J, Karlinsey J, Papenfort K, Vogel J, Fang FC (2009) Acid stress activation of the sigma(E) stress response in Salmonella enterica serovar Typhimurium. Mol Microbiol 71:1228–1238
Neoh SH, Rowley D (1970) The antigens of Vibrio cholerae involved in the vibriocidal action of antibody and complement. J Infect Dis 121:505–513
Ouellette AJ (2011) Paneth cell a-defensins in enteric innate immunity. Cell Mol Life Sci 68:2215–2229
Parkhill J, Dougan G, James KD, Thomson NR, Pickard D, Wain J, Churcher C, Mungall KL, Bentley SD, Holden MT, Sebaihia M, Baker S, Basham D, Brooks K, Chillingworth T, Connerton P, Cronin A, Davis P, Davies RM, Dowd L, White N, Farrar J, Feltwell T, Hamlin N, Haque A, Hien TT, Holroyd S, Jagels K, Krogh A, Larsen TS, Leather S, Moule S, O’Gaora P, Parry C, Quail M, Rutherford K, Simmonds M, Skelton J, Stevens K, Whitehead S, Barrell BG (2001) Complete genome sequence of a multiple drug resistant Salmonella enteric serovar Typhi CT18. Nature 413:848–852
Pasetti MF, Levine MM, Sztein MB (2003) Animal models paving the way for clinical trials of attenuated Salmonella enterica serovar Typhi live oral vaccines and live vectors. Vaccine 21:401–418
Pasetti MF, Simon JK, Sztein MB, Levine MM (2011) Immunology of gut mucosal vaccines. Immunol Rev 239:125–148
Pasquali P, Adone R, Gasbarre LC, Pistoia C, Petrucci P, Ciuchini F (2003) Brucella abortus RB51 induces protection to mice orally infected with virulent strain B.abortus 2308. Infect Immun 71:2326–2330
Pasquali P, Ammendola S, Pistoia C, Petrucci P, Tarantino M, Rotilio G, Battistoni A (2008) Attenuated Salmonella enterica serovar Typhimurium lacking ZnuABC transporter (S.Typhimurium SA 186) confer immune-based protection against challenge infections in mice. Vaccine 26:3421–3426
Pesciaroli M, Ammendola S, Pistoia C, Petrucci P, Tarantino M, Battistoni A, Pasquali P (2011) Attenuated Salmonella enterica serovar Typhimurium lacking ZnuABC transporter (S.Typhimurium SA 186) confers immune-based protection against challenge infections in streptomycin pretreated mice. Vaccine 29:1783–1790
Petrarca P, Ammendola S, Pasquali P, Battistoni A (2010) The Zur-regulated ZinT protein is an auxiliary component of the high affinity ZnuABC zinc transporter that facilitates metal recruitment during severe zinc shortage. J Bacteriol 192:1553–1564
Podolski DK (2002) Inflammatory bowel disease. N Engl J Med 347:417–429
Qadri F, Chowdhury MI, Faruque SM, Salam MA, Ahmed T, Begum YA, Saha A, Alam MS, Zaman K, Seidlein LV, Park E, Killeen KP, Mekalanos JJ, Clemens JD, Sack DA, Peru-15 Study Group (2005) Randomized, controlled study of the safety and immunogenicity of Peru-15, a live attenuated oral vaccine candidate for cholera, in adult volunteers in Bangladesh. J Infect Dis 192:573–579
Qadri F, Chowdhury MI, Faruque SM, Salam MA, Ahmed T, Begum YA, Saha A, Al Tarique A, Seidlein LV, Park E, Killeen KP, Mekalanos JJ, Clemens JD, Sack DA, PXV Study Group (2007) Peru-15, a live attenuated oral cholera vaccine, is safe and immunogenic in Bangladeshi toddlers and infants. Vaccine 25:231–238
Quiding-Järbrink M, Nordström I, Granström G, Kilander A, Jertborn M, Butcher EC, Lazarovits AI, Holmgren J, Czerkinsky C (1997) Differential expression of tissue-specific adhesion molecules on human circulating antibody-forming cells after systemic, enteric, and nasal immunizations. A molecular basis for the compartmentalization of effector B cell responses. J Clin Invest 99:1281–1286
Raffatellu M, Wilson RP, Winter SE, Bäumler AJ (2008) Clinical pathogenesis of typhoid fever. J Infect Dev Ctries 2:260–266
Richie EE, Punjabi NH, Sidharta YY, Peetosutan KK, Sukandar MM, Wasserman SS, Lesmana MM, Wangsasaputra FF, Pandam SS, Levine MM, O’Hanley PP, Cryz SJ, Simanjuntak CH (2000) Efficacy trial of single-dose live oral cholera vaccine CVD 103-HgR in North Jakarta, Indonesia, a cholera-endemic area. Vaccine 18:2399–2410
Salmi M, Jalkanen S (2005) Lymphocyte homing to the gut: attraction, adhesion, and commitment. Immunol Rev 206:100–113
Samandari T, Kotloff KL, Losonsky GA, Picking WD, Sansonetti PJ, Levine MM, Sztein MB (2000) Production of IFN-γ and IL-10 to Shigella invasins by mononuclear cells from volunteers orally inoculated with a shiga toxin-deleted Shigella dysenteriae type 1 strain. J Immunol 164:2221–2232
Sanchez J, Holmgren J (2005) Virulence factors, pathogenesis and vaccine protection in cholera and ETEC diarrhea. Curr Opin Immunol 17:388–398
Sanchez JL, Vasquez B, Begue RE, Meza R, Castellares G, Cabezas C, Watts DM, Svennerholm AM, Sadoff JC, Taylor DN (1994) Protective efficacy of oral whole-cell/recombinant-B-subunit cholera vaccine in Peruvian military recruits. Lancet 344:1273–1276
Shin S, Desai SN, Sah BK, Clemens JD (2011) Oral vaccines against cholera. Clin Infect Dis 52:1343–1349
Soloff AC, Barratt-Boyes SM (2010) Enemy at the gates: dendritic cells and immunity to mucosal pathogens. Cell Res 20:872–885
Spangler BD (1992) Structure and function of cholera toxin and the related Escherichia coli heat-labile enterotoxin. Microbiol Rev 56:622–647
Strockbine NA, Maurelli AT (2005) Bergey’s manual of systematic bacteriology. Brenner, New York
Strugnell RA, Wijburg OL (2010) The role of secretory antibodies in infection immunity. Nat Rev Microbiol 8:656–667
Sur D, Lopez AL, Kanungo S, Paisley A, Manna B, Ali M, Niyogi SK, Park JK, Sarkar B, Puri MK, Kim DR, Deen JL, Holmgren J, Carbis R, Rao R, Nguyen TV, Donner A, Ganguly NK, Nair GB, Bhattacharya SK, Clemens JD (2009) Efficacy and safety of a modified killed-whole-cell oral cholera vaccine in India: an interim analysis of a cluster-randomised, double-blind, placebo-controlled trial. Lancet 374:1694–1702
Tacket CO, Losonsky G, Nataro JP, Cryz SJ, Edelman R, Kaper JB, Levine MM (1992) Onset and duration of protective immunity in challenged volunteers after vaccination with live oral cholera vaccine CVD 103-HgR. J Infect Dis 166:837–841
Tarr PI, Gordon CA, Chandler WL (2005) Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet 365:1073–1086
Taylor DN, Cardenas V, Sanchez JL, Bégué RE, Gilman R, Bautista C, Perez J, Puga R, Gaillour A, Meza R, Echeverria P, Sadoff J (2000) Two-year study of the protective efficacy of the oral whole cell plus recombinant B subunit cholera vaccine in Peru. J Infect Dis 181:1667–1673
Thiem VD, Deen JL, von Seidlein L, Canh do G, Anh DD, Park JK, Ali M, Danovaro-Holliday MC, Son ND, Hoa NT, Holmgren J, Clemens JD (2006) Long-term effectiveness against cholera of oral killed whole-cell vaccine produced in Vietnam. Vaccine 24:4297–4303
Valera R, García HM, Jidy MD, Mirabal M, Armesto MI, Fando R, García L, Fernández R, Año G, Cedré B, Ramírez M, Bravo L, Serrano T, Palma S, González D, Miralles F, Medina V, Nuñez F, Plasencia Y, Martínez JC, Mandarioti A, Lugones J, Rodríguez BL, Moreno A, González D, Baro M, Solis RL, Sierra G, Barbera R, Domínguez F, Gutiérrez C, Kouri G, Campa C, Menéndez J (2009) Randomized, double-blind, placebo-controlled trial to evaluate the safety and immunogenicity of live oral cholera vaccine 638 in Cuban adults. Vaccine 27:6564–6569
World Health Organization (2006) Future directions for research on enterotoxigenic Escherichia coli vaccines for developing countries. Wkly Epidemiol Rec 81:97
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Pasquali, P. (2012). Mucosal Vaccines for Enteric Bacterial Pathogens. In: Baschieri, S. (eds) Innovation in Vaccinology. Springer, Dordrecht. https://doi.org/10.1007/978-94-007-4543-8_10
Download citation
DOI: https://doi.org/10.1007/978-94-007-4543-8_10
Published:
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-007-4542-1
Online ISBN: 978-94-007-4543-8
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)